{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:44:30Z","timestamp":1789980270391,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0368-9","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:22:27Z","timestamp":1524151347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil"],"prefix":"10.1186","volume":"10","author":[{"given":"Terence","family":"Fullerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Binneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Delnomdedieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kupiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"368_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329\u201344.","journal-title":"N Engl J Med"},{"key":"368_CR2","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"368_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1567205013666160930112625","volume":"14","author":"AR Kamkwalala","year":"2017","unstructured":"Kamkwalala AR, Newhouse PA. Beyond acetylcholinesterase inhibitors: novel cholinergic treatments for Alzheimer's disease. Curr Alzheimer Res. 2017;14:377\u201392.","journal-title":"Curr Alzheimer Res"},{"key":"368_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","volume":"167","author":"S Woods","year":"2012","unstructured":"Woods S, Clarke NN, Layfield R, Fone KC. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br J Pharmacol. 2012;167:436\u201349.","journal-title":"Br J Pharmacol"},{"key":"368_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","volume":"5","author":"MJ Ramirez","year":"2013","unstructured":"Ramirez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013;5:15.","journal-title":"Alzheimers Res Ther"},{"key":"368_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","volume":"25","author":"LA Dawson","year":"2001","unstructured":"Dawson LA, Nguyen HQ, Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"368_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2202-7-36","volume":"7","author":"DE Lorke","year":"2006","unstructured":"Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006;7:36.","journal-title":"BMC Neurosci"},{"key":"368_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trci.2015.04.001","volume":"1","author":"G Maher-Edwards","year":"2015","unstructured":"Maher-Edwards G, Watson C, Ascher J, Barnett C, Boswell D, Davies J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2015;1:23\u201336.","journal-title":"Alzheimers Dement"},{"key":"368_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2174\/156720510791383831","volume":"7","author":"G Maher-Edwards","year":"2010","unstructured":"Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res. 2010;7:374\u201385.","journal-title":"Curr Alzheimer Res"},{"key":"368_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/gps.2562","volume":"26","author":"G Maher-Edwards","year":"2011","unstructured":"Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26:536\u201344.","journal-title":"Int J Geriatr Psychiatry"},{"key":"368_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","volume":"13","author":"D Wilkinson","year":"2014","unstructured":"Wilkinson D, Windfeld K, Colding-J\u00f8rgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13:1092\u20139.","journal-title":"Lancet Neurol"},{"key":"368_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neuropharm.2017.07.010","volume":"125","author":"IEM de Jong","year":"2017","unstructured":"de Jong IEM, Mork A. Antagonism of the 5-HT6 receptor\u2014preclinical rationale for the treatment of Alzheimer's disease. Neuropharmacology. 2017;125:50\u201363.","journal-title":"Neuropharmacology"},{"key":"368_CR13","first-page":"S794","volume":"7","author":"T Cornery","year":"2011","unstructured":"Cornery T, Zasadny K, Morris E, Antinew J, Bell J, Billing B, et al. Receptor occupancy of the 5-HT6 receptor antagonist SAM-760 in non-human primates and healthy human volunteers. Alzheimers Dement. 2011;7:S794\u2013S5.","journal-title":"Alzheimers Dement"},{"key":"368_CR14","first-page":"S21","volume":"97","author":"P Lockwood","year":"2015","unstructured":"Lockwood P, Bell J, Chen I, Miceli J, Macci K, Van Winkle J, et al. 5HT2a receptor occupancy (RO) in healthy subjects determined by positron emission tomography (PET) following single-dose administration of SAM760 (PF-05212377). Clin Pharmacol Ther. 2015;97:S21.","journal-title":"Clin Pharmacol Ther"},{"key":"368_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"368_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","volume":"158","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021\u201331.","journal-title":"Arch Intern Med"},{"key":"368_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2967\/jnumed.111.093419","volume":"53","author":"CA Parker","year":"2012","unstructured":"Parker CA, Gunn RN, Rabiner EA, Slifstein M, Comley R, Salinas C, et al. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012;53:295\u2013303.","journal-title":"J Nucl Med"},{"key":"368_CR18","unstructured":"Lundbeck. Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease. 2016. http:\/\/files.shareholder.com\/downloads\/AMDA-GGC00\/3235438829x0x909233\/08059975-77B9-42FB-BEBE-3B46FB36C39D\/Idalopirdine-update_UK.pdf . Accessed Mar 2017."},{"key":"368_CR19","unstructured":"Medscape. Two more Phase 3 trials of Alzheimer's drug idalopirdine fail. 2017. http:\/\/www.medscape.com\/viewarticle\/875632 . Accessed Mar 2017."},{"key":"368_CR20","unstructured":"Axovant Sciences. Axovant announces negative topline results of intepirdine Phase 3 MINDSET trial in Alzheimer's disease. 2017. http:\/\/investors.axovant.com\/news-releases\/news-release-details\/axovant-announces-negative-topline-results-intepirdine-phase-3 . Accessed Sept 2017."},{"key":"368_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/pst.1633","volume":"13","author":"C Chuang-Stein","year":"2014","unstructured":"Chuang-Stein C, Kirby S. The shrinking or disappearing observed treatment effect. Pharm Stat. 2014;13:277\u201380.","journal-title":"Pharm Stat"},{"key":"368_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1474-4422(14)70232-7","volume":"13","author":"LS Schneider","year":"2014","unstructured":"Schneider LS. Idalopirdine for Alzheimer's disease: written in the stars. Lancet Neurol. 2014;13:1063\u20135.","journal-title":"Lancet Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0368-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:42:59Z","timestamp":1604191379000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0368-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]},"assertion":[{"value":"25 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants (or their legal representative) provided written informed consent prior to screening, and the final study protocol, amendments, and informed consent documentation were reviewed and approved by the Institutional Review Boards or Ethics Committees at each participating center (listed in Additional file), including those that had not yet recruited participants when the study was terminated (Australia and France). The study was conducted in compliance with the declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of the manuscript for submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TF, BB, MD, PL, and JMa are employees of the study sponsor, Pfizer. JK and JB were employees of Pfizer at the time the study was conducted. JMi was a contracted employee of Pfizer at the time the study was conducted. WD participated in the design and execution of this study as a contracted Pfizer employee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"38"}}